Chugai Pharmaceutical Co Ltd, having its headquarters at Tokyo, Japan is the fifth largest pharmaceutical company in Japan having branch offices, manufacturing units, R&D laboratories, affiliates and subsidiaries situated all over the world. The company was initially launched as Chugai Shinyaku in 1925 as a pharmaceutical trading company which was subsequently incorporated during 1943. Chugai is involved in discovering, developing and selling of prescription drugs for cancer, infectious diseases, blood, bones, heart and cardiovascular related disorders, accruing the estimated sales of around 122+ million USD.

 

The company also has a wide range of non-prescription / OTC products in drugs and insecticide segments, diagnostic products such as enzyme-immunoassay kits & Deoxyribo Nucleic Acid-DNA artificial bone implants and internal fixation devices. The company has been spending almost 20 percent of proceeds from its net sales into the R&D which is supposed to be the zenith amongst all the pharmaceutical industries in Japan. Chugai has been amalgamated with the world renowned Switzerland based pharmaceutical giants known as Roche Group and has become its subsidiary since 2001. Chugai is focused to invent, produce and commercialize successfully for the pioneering therapeutic products to meet the various medical challenges. 

 

The company is gaining enormous fame all over the world today under the able leadership of OSAMU NAGAYAMA – the chairman & CEO. The product range of Chugai Group includes prescription medications for central nervous system-CNS, cardiovascular, respiratory, gastrointestinal & metabolic systems, hormones & diagnostic products as well as an array of OTC drugs. However, the flagship product line of Chugai Pharmaceutical Co Ltd includes: Epogin, Alfarol, Neutrogin, Sigmart, Suvenyl, Oxarol, Rocephin, Varsan, Euglucon, Renagel and Rythmodan.